Joe Bress is a Principal at The Carlyle Group, focusing on private equity opportunities in the healthcare sector. He is based in New York.
Since joining Carlyle in 2007, Mr. Bress has been involved in investing and managing more than $4 billion of equity investments in health care companies globally. He currently sits on the boards of Pharmaceutical Product Development (PPD), WellDyneRx, Albany Molecular Research, Visionary RCM, Millicent Pharma and X-Co (the parent company of X-Chem and X-Rx). He is also involved in Carlyle’s investment in Rede D’Or Sao Luiz and was previously involved in Carlyle’s realized investments in MultiPlan, HCR ManorCare and MedPointe. Prior to Carlyle, Mr. Bress worked in the Mergers and Acquisitions group at UBS.
He received an MBA from Stanford University’s Graduate School of Business and an AB from Harvard College, where he graduated magna cum laude.